YMAB News and Press, Y-mAbs Therapeutics Inc. From 03/31/23

2023-03-31 10:05:49 ET Gainers: Y-mAbs Therapeutics ( YMAB ) +43% . G Medical Innovations ( GMVD ) +41% . Palisade Bio ( PALI ) +20% . Inozyme Pharma ( INZY ) +17% . Paratek Pharmaceuticals ( PRTK ) +17% . Losers: Pyxis...

2023-03-30 17:59:02 ET Y-mAbs Therapeutics ( NASDAQ: YMAB ) has filed for a $150M mixed shelf offering. The filing does not necessarily indicate that a sale has begun or will occur in the future. The offering may include common stock, preferred stock, warrants, debt se...

2023-03-30 16:39:30 ET Y-mAbs Therapeutics press release ( NASDAQ: YMAB ): FY GAAP EPS of -$2.19 beats by $0.46 . Revenue of $65.27M (+87.0% Y/Y) beats by $11.88M . For further details see: Y-mAbs Therapeutics GAAP EPS of -$2.19 beats by $0.46, revenue of...

Q4 2022 DANYELZA® record net product revenues of $16.4 million, driving YoY growth of 71% and 31% sequential increase compared to Q3 2022 DANYELZA conditional marketing authorization granted in China Management reiterates 2023 financial guidance First ever SADA Phase ...

NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for year ended December 31, 2022, on Thursday, March 30, 2023, after the close of the U.S. financ...

Summary Last year, the FDA hit YMAB with a CRL for its neuroblastoma drug omburtamab. The company will need to do a new trial to get approval. Their restructuring will get them through mid-2024 with existing cash. For further details see: Y-mAbs Therapeutic...

New York, New York--(Newsfile Corp. - February 27, 2023) - Levi & Korsinsky, LLP notifies investors in Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) of a class action securities lawsuit. The lawsuit on behalf of Y-mAbs investors has been commenced in the the United S...

Y-mAbs Therapeutics ( NASDAQ: YMAB ) said the European Medicines Agency had agreed to its proposed pediatric investigation plan for naxitamab to treat patients with relapsed/refractory high-risk neuroblastoma. A Pediatric Investigation Plan outlines a pharma company’s strategy ...

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatmen...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - January 27, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is ...